Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan

Kidney International

Volumn 64, Issue 4, 2003, Pages 1445-1449

  Usami, Takeshi ^a   Nakao, Naoyuki ^a   Fukuda, Michio ^a   Takeuchi, Oki ^a   Kamiya, Yoshinobu ^a   Yoshida, Atsuhiro ^a   Kimura, Genjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Angiotensin converting enzyme inhibitors; Antihypertensive therapy; Chronic renal failure; End stage renal disease; Incidence; Prevention; Regional difference; Risk factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANALYSIS OF VARIANCE; ARTICLE; CALCULATION; CORRELATION ANALYSIS; DIALYSIS; DRUG COST; GENETIC ANALYSIS; GEOGRAPHY; HEALTH CARE ORGANIZATION; HUMAN; INCIDENCE; JAPAN; KIDNEY FAILURE; LINEAR REGRESSION ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEASUREMENT; MULTIPLE REGRESSION; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0141674869     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00221.x     Document Type: Article

References (20)

1. USAMI T, KOYAMA K, TAKEUCHI O, et al: Regional variations in the incidence of end-stage renal failure in Japan. JAMA 284:2622-2624, 2000
2. USAMI T, SATO R, YOSHIDA A, KIMURA G: Regional variation in end-stage renal disease. Curr Opin Nephrol Hypertens 11:343-346, 2002
3. KLAHR S, LEVERY AS, BECK GJ, et al: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994
4. KLAG MJ, WHELTON PK, RANDALL BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996
5. ZATZ R, DUNN BR, MEYER TW, et al: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
6. ANDERSON S, RENNKE HG, BRENNER BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
7. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD, FOR THE COLLABORATIVE STUDY GROUP: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
8. BRENNER BM, LAWLER EV, MACKENZIE HS: The hyperfiltration theory: A paradigm shift in nephrology. Kidney Int 49:1774-1777, 1996
9. AGODOA LY, APPEL L, BAKRIS GL, et al: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285:2719-2728, 2001
10. NAKAO N, YOSHIMURA A, MORITA H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361:117-124, 2003
11. JAP SDT: An overview of regular dialysis treatment in Japan (as of Dec. 31, 2000). Tokyo, Jpn Soc Dial Ther, 2001
12. STATISTICS BUREAU AND STATISTICS CENTER: Annual report on current population estimates (as of October 1, 2001). Tokyo, Management and Coordination Agency of Japan, 2001
13. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
14. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352:1252-1256, 1998
15. HANNEDOUCHE T, LANDAIS P, GOLDFARB B, et al: Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. Br Med J 309:833-837, 1994
16. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
17. THE GISEN GROUP: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
18. JAFAR TH, SCHMID CH, LANDA M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
19. THE SIXTH REPORT OF THE JOINT NATIONAL COMMITTEE ON PREVENTION: Detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997
20. WORLD HEALTH ORGANIZATION-INTERNATIONAL SOCIETY OF HYPERTENSION GUIDELINES FOR THE MANAGEMENT OF HYPERTENSION: Guidelines Subcommittee. J Hypertens 17:151-183, 1999